New Study Highlights Extended Life Span in Mice
Recent research from the University of California, Berkeley, indicates that GLP-1 drugs might extend beyond their current uses for obesity and type 2 diabetes treatment, potentially prolonging life span. This study, published in Nature on September 2, found that semaglutide treatment lengthened the life span of female mice by mitigating aging’s detrimental effects.
Danica Chen, one of the study’s authors and a professor at UC Berkeley, suggests the findings may allow expanding GLP-1 medicines to healthy individuals to delay aging.
Mechanism and Popularity of GLP-1 Drugs
Known as Ozempic and Wegovy, GLP-1 drugs diminish ‘food noise,’ the persistent thoughts about eating. They mimic a hormone that induces fullness and slows digestion, leading to reduced appetite and balanced blood sugar levels. These drugs have gained popularity for diabetes and obesity, with one in eight Americans using them by March 2026, according to Statista.
“These medications have paralleled a decrease in U.S. obesity rates,” experts note, while advising caution due to multiple influencing factors.
Study Methodology and Findings
Researchers administered semaglutide to 20-month-old female mice via injection, observing their life span increase from 742 days to 834 days. Mice experienced a 24% appetite reduction, decreased body and tissue weight. Chen noted improvements in physiological functions and aging markers.
Despite its significance, the results are within expectations, as noted by Richard DiMarchi, a chemistry professor at Indiana University. He emphasizes the challenges of translating findings from mice to humans due to genetic differences.
Potential Human Impact and Expert Opinions
Randy Seeley, a professor at the University of Michigan, acknowledges data from trials showing reduced mortality and possible life span extension with GLP-1 drugs. He points to cardiovascular health effects as a possible mechanism, cautioning that initial fears of heightened cardiovascular risks have not been validated.
Chen states that semaglutide’s impact on life span likely involves factors beyond calorie reduction, warranting further study.
Seeley adds that GLP-1s might reduce inflammation, though the means by which this occurs remain unclear. The drug’s potential effects on immune cells, metabolic fuel utilization, and brain regulation of immune function require more research.
“We remain in the process of understanding these mechanisms,” Seeley explains.
Reference: Feng, Y., Barthez, M., Wang, Y. et al. (2026). Late-life semaglutide treatment slows aging and extends life span in female mice. Nature. https://doi.org/10.1038/s41586-026-10940-7
Contact Newsweek editors on this story: Kara Dolman and James Debens